Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus -LUNA Trial

Phase 2

Completed

• Conditions: Lung carcinoid; Neuroendocrine tumor of the thymus; 10029112; 10014713; 10029107

• Registration Number: NL-OMON40411
• Lead Sponsor: ovartis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 8

Inclusion Criteria

* Histological confirmed advanced well differentiated carcinoma of the lung and thymus;* Patients of all treatment lines can be included;* At least one measurable lesion of disease on CT scan or MRI;* Radiological documentation of disease progression within 12 months prior to randomization;* Adequate liver, renal and bone marrow function;* WHO performancestatus 0-2;Other protocol-defined inclusion criteria may apply

Exclusion Criteria

* Poorly differentiated neuroendocrine carcinoma;* Non-neuroendocrine thymoma;* Patients with severe functional disease requiring symptomatic treatment with somatostatin analogs;* Prior therapy with mTOR inhibitors;* History of liver disease;* Baseline QTcF> 470 msec;* Uncontrolled diabetes mellitus despite adequate therapy;Other protocol-defined exclusion criteria may apply

Study & Design

• Study Type: Interventional
• Study Design: Not specified